(126 days)
Not Found
No
The device description details a lateral flow immunoassay based on antigen-antibody reactions, which is a purely chemical and physical process. There is no mention of any computational analysis, algorithms, or learning processes that would indicate the use of AI or ML. The performance studies also focus on the chemical detection capabilities and reproducibility, not on algorithmic performance.
No.
This device is a diagnostic tool used to detect the presence of benzyl ecgonine (a cocaine metabolite) in urine, which helps in identifying drug use, not in treating a disease or condition.
Yes
The device is intended for the detection of benzyl ecgonine in urine, which serves as a preliminary screening method to identify the presence of a substance in the body, thus aiding in the diagnostic process for drug use.
No
The device description clearly outlines a physical, lateral flow immunoassay strip that utilizes chemical reactions and a membrane. This is a hardware-based diagnostic test, not software.
Based on the provided information, the 'RapidOne' - Cocaine Test is indeed an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use explicitly states it is for the "detection of benzyl ecgonine in urine" and for the "qualitative detection of benzyl ecgonine in human urine". This involves testing a sample taken from the human body (urine) in vitro (outside the body) to gain information about a physiological state (presence of cocaine metabolite).
- Device Description: The description details a "lateral flow immunoassay" that uses a "membrane strip" and "colloidal gold-antibody complex" to detect the presence of a substance in the urine sample. This is a typical format for many IVD tests.
- Performance Studies: The document describes performance studies comparing the device to a predicate device and evaluating reproducibility using urine samples. This is standard practice for demonstrating the performance of an IVD.
- Predicate Device: The mention of a predicate device (K971957; Forefront Diagnostics, Inc. 'Instacheck' Drug Screen -Cocaine Test) which is also a drug screening test, further supports its classification as an IVD.
Therefore, the 'RapidOne' - Cocaine Test fits the definition of an In Vitro Diagnostic device.
N/A
Intended Use / Indications for Use
'RapidOne'- Cocaine Test is used for the qualitative detection of benzoyl ecgonine in human urine. This immunoassay is a simplified qualitative screening method that provides only a preliminary result for use in determining the need for additional or confirmatory testing, i.e., gas chromatography/mass spectrometry (GC/Ms).
'RapidOne' - Cocaine Test is a one-step, lateral flow immunoassay for the detection of benzyl ecgonine in urine. 'RapidOne' - Cocaine Test is intended for use in the qualitative detection of benzyl ecgonine in human urine at 300 ng/ml.
'RapidOne' - Cocaine Test is intended for professional use. It is not intended for over the counter sale to non-professionals. The assay is easy to perform, but should not be used without proper supervision. This immunoassay is a simplified qualitative screening method that provides only a preliminary result for use in determining the need for additional or confirmatory testing, i.e., gas-chromatography/mass spectrometry (GC/MS) or HPLC.
'RapidOne' - Cocaine Test provides only a preliminary analytical test result. A more specific alternate chemical method must be used in order to obtain a more confirmed analytical result. Gas chromatography/mass spectrometry (GC/MS) is the preferred confirmatory method. Clinical and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are used.
Product codes (comma separated list FDA assigned to the subject device)
DIO
Device Description
The assay employed in the 'RapidOne'- Cocaine Test is based on the same principle of highly specific reaction between antigens and antibodies.
Each assay is a one-step, immunoassay in which a specially labeled drug (drug conjugate) competes with drug which may be present in the sample for the limited number of binding sites on the antibody. The test device consists of a membrane strip onto which a drug conjugate has been immobilized. A colloidal gold-antibody complex is dried at one end of the membrane. In the absence of any drug in the urine sample, the colloidal goldantibody complex moves with the urine by capillary action to contact the immobilized drug conjugate. An antibody-antigen reaction occurs forming a visible line in the 'test' area. The formation of a visible line in the test area occurs when the test is negative.
When drug is present in the urine sample, the drug or metabolite will compete with the immobilized drug conjugate in the test area for the limited antibody sites on the colloidal gold-antibody complex. If sufficient amount of drug is present, it will fill all of the available binding sites, thus preventing attachment of the labeled antibody to the drug conjugate. An absence of a color band (line) in the test area is indicative of a positive result.
A control band (line), comprised of a different antibody/antigen reaction, is present on the membrane strip. The control line is not influenced by the presence of absence of drug in the urine, and therefore, should be present in all reactions.
A negative urine will produce two colored bands, and a positive sample will produce only one band.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
human urine
Indicated Patient Age Range
Not Found
Intended User / Care Setting
professional use
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
'RapidOne'-Cocaine Test was compared to 'Instacheck' Drug Screen-Cocaine Test. Ninety (90) samples were selected for evaluation, fifty (50) of which were found to be drug-free and thirty (40) tested as positive by Syva EMIT-II. The forty positive specimens were confirmed and quantified by GC/MS. Both immunoassays correctly identified all of the specimens which contained no drug as negative and determined the 40 drug-containing specimens, ranging in concentration of 249 ng/ml to 55,000 ng/ml, to be positive.
Reproducibility was evaluated using control urines containing concentrations above and below the stated cut-off. Negative urines were also used. Each sample, at each concentration of analyte, was tested 4 times, twice daily, for 5 days.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
| Conc. (ng/ml) | # | Result | Precision |
|---|---|---|---|
| 0 | 40 | 40/40 neg | >99% |
| 225 | 40 | 20/40 pos | 50% |
| 300 | 40 | 40/40 pos | >99% |
| 375 | 40 | 40/40 pos | >99% |
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 862.3250 Cocaine and cocaine metabolite test system.
(a)
Identification. A cocaine and cocaine metabolite test system is a device intended to measure cocaine and a cocaine metabolite (benzoylecgonine) in serum, plasma, and urine. Measurements obtained by this device are used in the diagnosis and treatment of cocaine use or overdose.(b)
Classification. Class II (special controls). A cocaine and cocaine metabolite test system is not exempt if it is intended for any use other than employment or insurance testing or is intended for Federal drug testing programs. The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9, provided the test system is intended for employment and insurance testing and includes a statement in the labeling that the device is intended solely for use in employment and insurance testing, and does not include devices intended for Federal drug testing programs (e.g., programs run by the Substance Abuse and Mental Health Services Administration (SAMHSA), the Department of Transportation (DOT), and the U.S. military).
0
JUL 15 1999
510(k) Summary
Submitter's Name/Address:
American Bio Medica Corporation 300 Fairview Avenue Hudson, N.Y. 12534
Contact Person:
Henry Wells Vice President of Product Development Phone: 518-822-8882 Fax: 518-822-0391
'RapidOne' - Cocaine Test
Date of Preparation of this Summary:
Device Trade of Proprietary Name:
Device Common/Usual Name or Classification Name:
June 3, 1999
Cocaine and cocaine metabolite test system
Classification Number/Class
21 C.F.R. § 862.3250 (Class II)
This 510(k) Summary is being submitted in accordance with the requirements of 21 CFR 807.92.
The assigned 510(k) is: K990822
Predicate Device: Forefront Diagnostics, Inc. 'Instacheck' Drug Screen -Cocaine Test (510(k) No. K971957)
Test Description:
The assay employed in the 'RapidOne'- Cocaine Test is based on the same principle of highly specific reaction between antigens and antibodies.
Each assay is a one-step, immunoassay in which a specially labeled drug (drug conjugate) competes with drug which may be present in the sample for the limited number of binding sites on the antibody. The test device consists of a membrane strip onto which a drug conjugate has been immobilized. A colloidal gold-antibody complex is dried at one end of the membrane. In the absence of any drug in the urine sample, the colloidal goldantibody complex moves with the urine by capillary action to contact the immobilized drug conjugate. An antibody-antigen reaction occurs forming a visible line in the 'test' area. The formation of a visible line in the test area occurs when the test is negative.
When drug is present in the urine sample, the drug or metabolite will compete with the immobilized drug conjugate in the test area for the limited antibody sites on the colloidal gold-antibody complex. If sufficient amount of drug is present, it will fill all of the available binding sites, thus preventing attachment of the labeled antibody to the drug conjugate. An absence of a color band (line) in the test area is indicative of a positive result.
1
A control band (line), comprised of a different antibody/antigen reaction, is present on the membrane strip. The control line is not influenced by the presence of absence of drug in the urine, and therefore, should be present in all reactions.
A negative urine will produce two colored bands, and a positive sample will produce only one band.
IntendedUse:
'RapidOne'- Cocaine Test is used for the qualitative detection of benzoyl ecgonine in human urine. This immunoassay is a simplified qualitative screening method that provides only a preliminary result for use in determining the need for additional or confirmatory testing, i.e., gas chromatography/mass spectrometry (GC/Ms).
Performance Characteristics:
'RapidOne'-Cocaine Test will detect 300 ng/ml of benzoyl ecgonine in urine.
'RapidOne'-Cocaine Test was compared to 'Instacheck' Drug Screen-Cocaine Test. Ninety (90) samples were selected for evaluation, fifty (50) of which were found to be drug-free and thirty (40) tested as positive by Syva EMIT-II. The forty positive specimens were confirmed and quantified by GC/MS. Both immunoassays correctly identified all of the specimens which contained no drug as negative and determined the 40 drug-containing specimens, ranging in concentration of 249 ng/ml to 55,000 ng/ml, to be positive.
Reproducibility was evaluated using control urines containing concentrations above and below the stated cut-off. Negative urines were also used. Each sample, at each concentration of analyte, was tested 4 times, twice daily, for 5 days.
| Conc. (ng/ml) | # | Result | Precision |
|---|---|---|---|
| 0 | 40 | 40/40 neg | >99% |
| 225 | 40 | 20/40 pos | 50% |
| 300 | 40 | 40/40 pos | >99% |
| 375 | 40 | 40/40 pos | >99% |
Conclusion:
'RapidOne'- Cocaine Test is substantially equivalent to 'Instacheck' - Drug Screen -Cocaine Test
2
Image /page/2/Picture/1 description: The image shows a logo for the Department of Health & Human Services - USA. The logo is circular, with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the perimeter of the circle. Inside the circle is a stylized image of a bird or other winged creature, with three lines representing the wings.
JUL 15 1999
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
American Bio Medica c/o Mr. John B. Dubeck KELLER AND HECKMAN LLP 1001 G Street, N.W. Suite 500 West Washington, D.C. 20001
Re: K990822 Trade Name: 'Rapid One' -- Cocaine test Regulatory Class: II Product Code: DIO Dated: June 16, 1999 Received: June 16, 1999
Dear Mr. Dubeck:
We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic OS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.
3
Page 2
Under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88), this device may require a CLIA complexity categorization. To determine if it does, you should contact the Centers for Disease Control and Prevention (CDC) at (770) 488-7655.
This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification"(21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597, or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".
Sincerely yours,
Steven Butman
Steven I. Gutman, M.D. M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
4
Page 1 of 1
K990822 510(k) Number (if known):
'RapidOne' - Cocaine Test Device Name:
Indications For Use:
'RapidOne' - Cocaine Test is a one-step, lateral flow immunoassay for the detection of benzyl ecgonine in urine. 'RapidOne' - Cocaine Test is intended for use in the qualitative detection of benzyl ecgonine in human urine at 300 ng/ml.
'RapidOne' - Cocaine Test is intended for professional use. It is not intended for over the counter sale to non-professionals. The assay is easy to perform, but should not be used without proper supervision. This immunoassay is a simplified qualitative screening method that provides only a preliminary result for use in determining the need for additional or confirmatory testing, i.e., gas-chromatography/mass spectrometry (GC/MS) or HPLC.
'RapidOne' - Cocaine Test provides only a preliminary analytical test result. A more specific alternate chemical method must be used in order to obtain a more confirmed analytical result. Gas chromatography/mass spectrometry (GC/MS) is the preferred confirmatory method. Clinical and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are used.
Sean Cooper
(Division Sign-Off)
Division of Clinical Laboratory Devices
510(k) Number K990822
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Prescription Use t (Per 21 CFR 801.109)
OR
Over-The-Counter Use
(Optional Format 1-2-96)